dc.contributor
Institut Català de la Salut
dc.contributor
[Williams T] Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, UK. Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, UK. [Tur C] Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, UK. Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Eshaghi A, Doshi A] Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, UK. [Chan D] UCL Institute of Cognitive Neuroscience, University College London, London, UK. [Binks S] Department of Neurology, Nuffield Department of Clinical Neurosciences, Oxford, UK
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Williams, Thomas
dc.contributor.author
Tur Gomez, Carmen
dc.contributor.author
Doshi, Anisha
dc.contributor.author
Chan, Dennis
dc.contributor.author
Binks, Sophie
dc.contributor.author
Eshaghi, Arman
dc.date.issued
2022-12-13T10:41:30Z
dc.date.issued
2022-12-13T10:41:30Z
dc.identifier
Williams T, Tur C, Eshaghi A, Doshi A, Chan D, Binks S, et al. Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial. Mult Scler J. 2022 Oct;28(12):1913–26.
dc.identifier
https://hdl.handle.net/11351/8664
dc.identifier
10.1177/13524585221114441
dc.identifier
000839253300001
dc.description.abstract
Magnetic resonance imaging; Neurofilament light; Secondary progressive multiple sclerosis
dc.description.abstract
Imatge per ressonància magnètica; Llum del neurofilament; Esclerosi múltiple secundària progressiva
dc.description.abstract
Imagen por resonancia magnética; Luz de neurofilamento; Esclerosis múltiple secundaria progresiva
dc.description.abstract
Background:
Cognitive impairment affects 50%–75% of people with secondary progressive multiple sclerosis (PwSPMS). Improving our ability to predict cognitive decline may facilitate earlier intervention.
Objective:
The main aim of this study was to assess the relationship between longitudinal changes in cognition and baseline serum neurofilament light chain (sNfL) in PwSPMS. In a multi-modal analysis, MRI variables were additionally included to determine if sNfL has predictive utility beyond that already established through MRI.
Methods:
Participants from the MS-STAT trial underwent a detailed neuropsychological test battery at baseline, 12 and 24 months. Linear mixed models were used to assess the relationships between cognition, sNfL, T2 lesion volume (T2LV) and normalised regional brain volumes.
Results:
Median age and Expanded Disability Status Score (EDSS) were 51 and 6.0. Each doubling of baseline sNfL was associated with a 0.010 [0.003–0.017] point per month faster decline in WASI Full Scale IQ Z-score (p = 0.008), independent of T2LV and normalised regional volumes. In contrast, lower baseline volume of the transverse temporal gyrus was associated with poorer current cognitive performance (0.362 [0.026–0.698] point reduction per mL, p = 0.035), but not change in cognition. The results were supported by secondary analyses on individual cognitive components.
Conclusion:
Elevated sNfL is associated with faster cognitive decline, independent of T2LV and regional normalised volumes.
dc.description.abstract
The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: No specific funding was received for this research. T.W. is currently funded by the MS-STAT2 trial grant (NCT03387670). This is funded by the NIHR Health Technology Assessment (HTA) Programme, Multiple Sclerosis Society (UK) and the National Multiple Sclerosis Society (US).
dc.format
application/pdf
dc.publisher
SAGE Publications
dc.relation
Multiple Sclerosis Journal;28(12)
dc.relation
https://doi.org/10.1177/13524585221114441
dc.rights
Attribution-NonCommercial 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Esclerosi múltiple - Imatgeria
dc.subject
Trastorns de la cognició - Imatgeria
dc.subject
PSYCHIATRY AND PSYCHOLOGY::Mental Disorders::Neurocognitive Disorders::Cognition Disorders::Cognitive Dysfunction
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Amino Acids, Peptides, and Proteins::Proteins::Nerve Tissue Proteins::Neurofilament Proteins
dc.subject
DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis
dc.subject
Other subheadings::Other subheadings::Other subheadings::/diagnostic imaging
dc.subject
PSIQUIATRÍA Y PSICOLOGÍA::trastornos mentales::trastornos neurocognitivos::trastornos cognitivos::disfunción cognitiva
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::aminoácidos, péptidos y proteínas::proteínas::proteínas del tejido nervioso::proteínas de neurofilamentos
dc.subject
ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/diagnóstico por imagen
dc.title
Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
